Search Criteria: Research Area is "Cancer Research: Increased Tumor Incidence (Lymphomas: B cell lymphomas)"
| Stock Number |
Strain Name Strain Description |
Standard Supply |
| 007263 | B6.129S1-Ing1tm1Avg/J | Repository- Live |
| Mice homozygous for the targeted mutation are viable, fertile, and do not display any gross physical or behavioral abnormalities. Homozygotes are smaller than their wildtype littermates. Homozygous births from heterozygous crosses occur at a lower than expected frequency. During a 23 month period homozygotes exhibit increased morbidity or visible abnormalities including splenomegaly and an increased incidence of lymphomas (follicular center B-cell lymphomas) when compared to wild type littermates. When exposed to 6 consecutive daily doses of 2.34Gy total body gamma irradiation, mutant mice have a lower survival rate than wildtype controls. Mouse embryonic fibroblasts (MEFs) from homozygous animals are slightly more sensitive to UV-B exposure. This mutant mouse strain may be useful in studies of hypersensitivity to gamma irradiation and tumorigenesis. | ||
| 002728 | B6.Cg-Tg(IghMyc)22Bri/J | Repository- Live |
| Expression of the mouse Myc transgene is restricted to the B cell lineage. Hemizygotes show increased pre-B cells in the bone marrow throughout life and a transient increase in large pre-B cells in the blood at 3-4 weeks of age. Spontaneous pre-B and B cell lymphomas reach an incidence of 50% at 15-20 weeks in hemizygous progeny of a wildtype female mated with a hemizygous male. The transgene synergizes with an TgN(BCL2)22Wehi transgene (Stock No. 02319) to produce primitive lymphoid tumors within 5 weeks of birth, and with an Emu-v-abl transgene to produce plasmacytomas by 8 weeks. | ||
| 008332 | C.129S1-Ightm1Janz/J | Repository- Live |
| These mutant mice carry a His6-tagged Myc gene (cDNA) sequence inserted in the endogenous immunoglobulin heavy chain complex (Igh) locus, which mimics the human endemic Burkitt lymphoma t(8;14)(q24;q32) translocation and mouse plasmacytoma T(12;15) translocation.
The His6-tagged Myc is overexpressed in B-cells throughout B-cell development, as detected by FACS analysis. Tumor-free heterozygotes, 4 to 6 months of age, on a mixed B6;129X1 background, exhibit increased B-cell proliferation and apoptosis and have enlarged lymph nodes and spleen due to follicular hyperplasia. 68% of mutant mice between 6 and 21 months of age develop mature B-cell tumors that are IgM and BCL6 positive. Approximately half of the tumors detected are lymphoblastic B-cell lymphomas that are Burkitt-like in appearance and one fifth as plasmacytomas. The plasmacytomas occur in gut-associated lymphoid tissue (GALT), especially in the mesenteric lymph node and Peyer's
..... For more information please see the full descriiption on the strain data sheet | ||
| 008183 | B6.129S4(Cg)-Trp53tm2.1Tyj/J | Repository-Cryopreserved |
| Mice carrying this Trp53 (p53) R172H point mutation mimic human Li-Fraumeni Syndrome, both genotypically and phenotypically. Heterozygotes develop a broad spectrum of tumors with a mean survival time of 16 months. Prominent tumor types include osteosarcomas (often metastatic), hemangiosarcomas, B-cell lymphomas and a variety of carcinomas. Homozygous mice also develop a broad spectrum of tumors, particularly T-cell lymphomas, hemangiosarcomas, soft-tissue sarcomas, osteosarcomas, primitive tumors (particularly male teratocarcinomas), and a variety of epithelial carcinomas. Mutant protein is expressed at high levels in mouse embryonic fibroblasts, as determined by Western blotting. | ||
| 008182 | B6.129S4-Trp53tm3.1Tyj/J | Repository-Cryopreserved |
| These targeted mutant mice carry a R270H missense mutation in exon 8 of the gene. Heterozygous mice develop a broad spectrum of tumors with a mean survival time of 16 months. Prominent tumor types include osteosarcomas (often metastatic), hemangiosarcomas, B-cell lymphomas and a variety of carcinomas. Homozygous mice also develop an array of tumor types including a variety of hematological tumors (particularly T-cell lymphomas), hemangiosarcomas, soft-tissue sarcomas, ostersarcomas, primitive tumors (particularly male teratocarcinomas), and a variety of epithelial carcinomas. Homozygotes have a mean survival time of 4.5 months. Mutant protein is expressed in all of the places that wildtype protein is expressed in normal tissues. Irradiation or DNA damage leads to substantially increased protein levels. Expression is also upregulated in some tumor types. This strain may be useful in studies of cancer and Li-Fraumeni Syndrome. | ||
| 004338 | B6;129-E2f2tm1Zubi/J | Repository-Cryopreserved |
| Mice that are homozygous for the targeted mutation are viable and normal in size. No gene product, mRNA or protein, was detected. At age 15 months mutant mice have a 27% survival rate due to diffuse autoimmune disease that resembles systemic lupus erythematosus (SLE). The phenotype includes splenomegaly by 8-12 weeks of age, glomerulonephritis, accumulated inflammatory infiltrates in the lung, liver, and skin abnormalities such as hair loss, skin wounds, erythema. Anti-dsDNA antibodies are detected in the serum. There are an increased number of mature CD8+ thymocytes and an abnormal accumulation of CD8+ Cd44high Cd69- T effector/memory cells that are autoreactive in peripheral lymphoid organs. E2F2 deficient mice appear to have normal negative selection of thymocytes but demonstrate defects in peripheral tolerance of T lymphoctes (especially Cd8+ T cells) leading to progressive autoimmune disease. This mutant mouse strain may be useful in studies of autoimmunity and may serve as model
..... For more information please see the full descriiption on the strain data sheet | ||
| 008181 | B6;129S4-Trp53tm4Tyj/J | Repository-Cryopreserved |
| Mice homozygous for this S23A point mutation are viable and fertile. Cells from the mice, including thymocytes and neurons in the cerebellum, exhibit defective apoptosis in response to DNA damage and exhibit partially impaired TRP53 (p53) stabilization. Mice develop increased lymphomas (especially B-cell lineage) and other tumors between one and two years of age. | ||
| 003395 | CD1-Tg(Igh-HOX11)11Idd/J | Repository-Cryopreserved |
| This transgenic strain is a good tool for developing therapies for non-Hodgkins lymphoma. Heterozygous mice appear normal and healthy at birth but die in their second year of life. More than 85% of of these mice die from mature B cell lymphoma. No homozygous TLX1 mice were identified in offspring of heterozygous matings, suggesting that homozygotes are not viable. | ||
(8 stocks) Back to Top
How to Register Interest
Please indicate your interest in purchasing any of the strains listed below when they become available for distribution by checking the box next to the strain(s) of interest and then selecting the "Continue" button which leads to an Interest Form.View a Data sheet for New Strains Under Development
Select the strain name to link to the strain data sheet.
New Strains Under DevelopmentThe Jackson Laboratory serves as a worldwide distributor and national repository for common and rare strains of inbred mice and mice carrying spontaneous mutations or induced mutations (i.e., transgenic, targeted/"knockout", or chemically induced mutations). At any one time, we have over 100 strains at various stages of development and colony expansion. Strains "Under Development" fall into two categories depending on the anticipated demand from the scientific community.
- Receive periodic updates on the status of the colony UNDER DEVELOPMENT
- Obtain advance notification of strain availability and opportunity to order prior to the strain being published as available
- Provide input affecting speed and quantity of availability
It is VERY IMPORTANT that you register interest in strains Under Development. The anticipated demand for a strain enables us to determine effectively the distribution plan for each strain Under Development. Registering interest also provides benefits to you (including advance notification of pending availability). Whether a strain is made available from a live colony OR from our cryopreservation repository, you may want to consider the option of Dedicated Supply. To learn more about Dedicated Supply, go to Services.
- Strains that will be made available from a live distribution colony at The Jackson Laboratory.
These strains are designated as: "Under Development for Distribution Colony"- Strains that will be made available through the Cryopreservation Repository.
These strains are designated as: "Under Development for Cryopreservation Repository"
Send questions to our Technical Support team using the Express Technical Support Form.
(3.2)